NCT06373822

Brief Summary

Objectives: To identify differentially expressed miRNAs in the blood of adenomyosis patients in view to develop new diagnostic methods Hypotheses Circulating miRNAs may be abnormally expressed in patients suffering from adenomyosis and could be used to diagnose the disease Study Design Blood samples will be collected from healthy subjects and adenomyosis patients and miRNAs will be isolated and analyzed to detect potential differences.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
64mo left

Started Mar 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Mar 2024Sep 2031

Study Start

First participant enrolled

March 21, 2024

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

April 15, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 18, 2024

Completed
7.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2031

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2031

Last Updated

April 22, 2024

Status Verified

April 1, 2024

Enrollment Period

7.5 years

First QC Date

April 15, 2024

Last Update Submit

April 18, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Circulating-miRNA as diagnostic biomarkers

    Sequencing miRNA

    Throughout the entire study, aproximately during 6,5 years

Study Arms (2)

Control group (N=25)

Female patients visiting the service de Gynécologie of the CUSL for the purpose of intervention in the context of a benign gynecological issue (myomectomy, endometrial resection etc). * Age ≥ 18 years * Pre-menopausal * Not HIV or Hepatitis-positive * Not having participated in another clinical study in the 12 months prior to recruitment * Not presenting symptoms of adenomyosis and/or endometriosis

Diagnostic Test: Circulating-mirna

Adenomyosis group (N=25)

Female patients visiting the service de Gynécologie of the CUSL for the purpose of surgical intervention in the context of uterine adenomyosis. * Age ≥ 18 years * Pre-menopausal * Not HIV or Hepatitis-positive * Not having participated in another clinical study in the 12 months prior to recruitment * Not presenting symptoms of endometriosis

Diagnostic Test: Circulating-mirna

Interventions

Circulating-mirnaDIAGNOSTIC_TEST

A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.

Adenomyosis group (N=25)Control group (N=25)

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Female patients visiting the service de Gynécologie of the CUSL for the purpose of surgical intervention in the context of uterine adenomyosis

You may qualify if:

  • Age ≥ 18 years
  • Pre-menopausal

You may not qualify if:

  • HIV or Hepatitis-positive
  • having participated in another clinical study in the 12 months prior to recruitment
  • presenting symptoms of endometriosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CUSL

Brussels, Woluwe-Saint-Lambert, 1200, Belgium

RECRUITING

MeSH Terms

Conditions

Adenomyosis

Condition Hierarchy (Ancestors)

Uterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2024

First Posted

April 18, 2024

Study Start

March 21, 2024

Primary Completion (Estimated)

September 1, 2031

Study Completion (Estimated)

September 1, 2031

Last Updated

April 22, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations